DRNA - Dicerna Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue295184-
Cost of Revenue---
Gross Profit295184-
Operating Expenses
Research Development41,69443,97129,453
Selling General and Administrative18,34919,24015,648
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-59,748-63,027-45,101
Income from Continuing Operations
Total Other Income/Expenses Net235188-2,639
Earnings Before Interest and Taxes-59,513-62,839-47,740
Interest Expense--199
Income Before Tax-59,513-62,839-47,939
Income Tax Expense---
Minority Interest---
Net Income From Continuing Ops-59,513-62,839-47,939
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-59,513-62,839-47,939
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-59,513-62,839-48,143